- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, July 28, 2023
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An opinion piece in The Hill referenced a study published in the June 2023 issue of The American Journal of Managed Care® (AJMC®). The study, “Income Differences Between Locations of 340B Entities and Contract Pharmacies,” found that 340B-covered hospitals and grantees were contracting with pharmacies in more affluent neighborhoods.
An article from Medical Xpress referenced a study to be published in the October 2023 issue of AJMC. The study, “Choosing Wisely Interventions to Reduce Antibiotic Overuse in the Safety Net,” evaluated the effect of Choosing Wisely on antibiotic prescribing in viral respiratory tract infections in a real-world safety-net setting.
An article from Becker’s Payer Issues referenced a study published in the July 2023 issue of AJMC. The study, “Social Determinants of Health and High-Cost Utilization Among Commercially Insured Population,” found that living in a disadvantaged neighborhood was associated with a higher likelihood of being a high-cost utilizer in older adults and lower likelihood in younger adults.
An article by HealthcareITNews referenced a contributor article published on AJMC.com, the website of AJMC. The article, “Contributor: Telehealth Utilization Grew 7% Nationally in January 2023,” featured statistics on how the utilization of telehealth had increased nationally in the first month of 2023.
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen
Oral GC Dose Tapering for MG Linked to Efgartigimod Initiation
August 25th 2025Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis: 3 months before starting efgartigimod and 3, 6, 9, and 12 months after starting efgartigimod.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
